Changes in the incidence and prevalence of human immunodeficiency virus or acquired immunodeficiency syndrome in the South African medical schemes environment: 2005-2015.
HIV or AIDS
South Africa
incidence
medical schemes
prevalence
Journal
Southern African journal of HIV medicine
ISSN: 2078-6751
Titre abrégé: South Afr J HIV Med
Pays: South Africa
ID NLM: 100965417
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
07
2019
accepted:
05
02
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
17
7
2020
Statut:
epublish
Résumé
The South African (SA) private medical schemes environment has over the past two decades respond to the evolving needs of people living with the human immunodeficiency virus (PLWH) or acquired immunodeficiency syndrome (AIDS). To determine changes in the incidence and prevalence rate of human immunodeficiency virus (HIV) or AIDS in the SA private medical schemes environment from 2005 to 2015. In this observational study, a single, pharmaceutical benefit management (PBM) company's medicine-claims database of members with HIV or AIDS has been retrospectively analysed from January 2005 to December 2015. The cohort includes all patients identified by the HIV or AIDS-related diagnostic ICD-10 codes, B20-B24, who also claimed antiretroviral medication during that period. From 2005 to 2015, the proportion of HIV or AIDS patients enrolled in the PBM-company increased from 0.63% to 2.10%, and the incidence rate of new cases among the beneficiaries increased 2.3 times. The highest HIV or AIDS prevalence and incidence rates were found in the age group ≥ 40 and < 60 years, followed by the age group ≥ 60 and < 70 years. The highest prevalence rates in 2015 were recorded in Gauteng, namely, 422.4/1000 beneficiaries, followed by Western Cape (149.4/1000), and KwaZulu-Natal (118.4/1000). There has been an increase in the number of SA-PLWH accessing treatment in the medical scheme environment. The high prevalence of HIV infection among older members should signal concern that HIV-related comorbid conditions are likely to become a growing component of care required by PLWH utilizing the SA private healthcare sector.
Sections du résumé
BACKGROUND
BACKGROUND
The South African (SA) private medical schemes environment has over the past two decades respond to the evolving needs of people living with the human immunodeficiency virus (PLWH) or acquired immunodeficiency syndrome (AIDS).
OBJECTIVE
OBJECTIVE
To determine changes in the incidence and prevalence rate of human immunodeficiency virus (HIV) or AIDS in the SA private medical schemes environment from 2005 to 2015.
METHOD
METHODS
In this observational study, a single, pharmaceutical benefit management (PBM) company's medicine-claims database of members with HIV or AIDS has been retrospectively analysed from January 2005 to December 2015. The cohort includes all patients identified by the HIV or AIDS-related diagnostic ICD-10 codes, B20-B24, who also claimed antiretroviral medication during that period.
RESULTS
RESULTS
From 2005 to 2015, the proportion of HIV or AIDS patients enrolled in the PBM-company increased from 0.63% to 2.10%, and the incidence rate of new cases among the beneficiaries increased 2.3 times. The highest HIV or AIDS prevalence and incidence rates were found in the age group ≥ 40 and < 60 years, followed by the age group ≥ 60 and < 70 years. The highest prevalence rates in 2015 were recorded in Gauteng, namely, 422.4/1000 beneficiaries, followed by Western Cape (149.4/1000), and KwaZulu-Natal (118.4/1000).
CONCLUSION
CONCLUSIONS
There has been an increase in the number of SA-PLWH accessing treatment in the medical scheme environment. The high prevalence of HIV infection among older members should signal concern that HIV-related comorbid conditions are likely to become a growing component of care required by PLWH utilizing the SA private healthcare sector.
Identifiants
pubmed: 32670625
doi: 10.4102/sajhivmed.v21i1.1007
pii: HIVMED-21-1007
pmc: PMC7343923
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1007Informations de copyright
© 2020. The Authors.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet HIV. 2017 Sep;4(9):e411-e422
pubmed: 28716545
PLoS One. 2018 Mar 12;13(3):e0194199
pubmed: 29529066
Antivir Ther. 2015;20(2):131-9
pubmed: 24704818
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
HIV Med. 2012 Sep;13 Suppl 2:1-85
pubmed: 22830364
BMC Infect Dis. 2017 Aug 9;17(1):551
pubmed: 28793863
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e17-24
pubmed: 23756374
Lancet HIV. 2019 Dec;6(12):e831-e859
pubmed: 31439534